Sirtex Sponsors Breakfast Symposia at the 2007 American Hepato-Pancreato-Biliary Association Annual Meeting

Sirtex, a leading developer of targeted and innovative cancer therapies, will sponsor a series of educational breakfast symposia at the 2007 American Hepato-Pancreato-Biliary Association (AHPBA) Annual Meeting to be held April 19-22 at the Bally’s Las Vegas in Las Vegas, Nev. Sirtex manufactures SIR-Spheres microspheres, the only FDA-approved microsphere therapy for metastatic colorectal cancer that has spread to the liver.1

The symposia, titled “Radioembolization Using Y-90 Microspheres for the Treatment of mCRC: Clinical Outcomes,” will be held Friday, April 20 starting at 6:30 a.m. The symposia consist of three consecutive sessions lasting approximately 30 minutes each. Andrew Kennedy, M.D., F.A.C.R.O., co-medical director of Wake Radiology Oncology in Cary, N.C., will serve as keynote speaker.

Kennedy’s presentation will include data from the largest study to date confirming the safety and efficacy of Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres in patients with unresectable liver tumors. The analysis included 680 treatments of SIR-Spheres microspheres in 515 patients. Kennedy will also discuss the latest safety and dosing data regarding patient selection and dosimetry for SIR-Spheres microspheres.

“Sirtex is pleased to participate in this year’s AHPBA meeting,” says Nat Geissel, CEO, Sirtex Medical Inc. “Our goal with the breakfast symposia is to educate and increase awareness of SIR-Spheres microspheres among the HPB and surgical oncology specialties. This open forum is an opportunity for physicians to learn more about using microspheres in conjunction with other oncology therapies to improve the level of patient care.”

The symposia will be held at the Bally’s Hotel in the Las Vegas ballroom III and IV. Physicians already registered for the AHPBA meeting are welcome to attend.

1 Sirtex Medical Inc.’s SIR-Spheres® microspheres are indicated for the treatment of non-resectable metastatic colorectal cancer in combination with intra-arterial FUDR chemotherapy. Information regarding other disease states or agents in combination with this device that is presented in peer-reviewed literature is different from the approved USA labeling for SIR-Spheres.

About Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres

Selective Internal Radiation Therapy (SIRT) is a novel treatment for inoperable liver cancer that delivers high doses of radiation directly to the site of tumors. In a minimally-invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.

Clinical trials have confirmed that liver cancer patients treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity, and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.

SIRT using SIR-Spheres microspheres is approved for use in Australia, New Zealand, the United States of America (FDA approval), European Union (CE Mark), Hong Kong, Malaysia, Singapore, Thailand, Israel, and India. SIRT is available in 140 treatment centers around the world, and more than 6500 patients have been treated to date.

Approximately 90 physicians in the United States use Sirtex’s SIR-Spheres microspheres in more than 86 medical centers. For more information, visit www.sirtex.com.

® SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd